Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Agnieszka Maj-Hes"'
Autor:
Maximilian J. Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, Angelika M. Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Prager, Wolfgang W. Lamm, Anna S. Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer
Publikováno v:
Infectious Agents and Cancer, Vol 18, Iss 1, Pp 1-10 (2023)
Abstract Background Patients with cancer are at high risk for severe courses of COVID-19. Based on (pre-)clinical data suggesting a potential protective effect due to the immunomodulating properties of azithromycin, we have initiated a prospective ra
Externí odkaz:
https://doaj.org/article/ea5d091cfe5e4460a474548a11cbcfca
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionMetastatic biliary tract cancer (BTC) is a rare and aggressive entity associated with poor prognosis. It represents a major challenge for adequate treatment strategies. In recent years, BTC has become a model for precision medicine in gas
Externí odkaz:
https://doaj.org/article/608c837b291245f685c2d2a99d680b7e
Autor:
Anita Csizmarik, Dávid Keresztes, Nikolett Nagy, Thilo Bracht, Barbara Sitek, Kathrin Witzke, Martin Puhr, Ilona Tornyi, József Lázár, László Takács, Gero Kramer, Sabina Sevcenco, Agnieszka Maj‐Hes, Zsolt Jurányi, Boris Hadaschik, Péter Nyirády, Tibor Szarvas
Publikováno v:
International Journal of Cancer. 151:1405-1419
Enzalutamide (ENZA) is a frequently used therapy in metastatic castration-resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9412f9f8d4882f291e4b4de34d5f428f
https://doi.org/10.1002/ijc.34159
https://doi.org/10.1002/ijc.34159
Publikováno v:
Advances in Therapy
Introduction: This study aimed to assess the effects of multiple docetaxel (DOC) treatments on prostate-specific antigen (PSA) kinetics and survival among patients with metastatic castration-resistant prostate cancer (mCRPC) who were sensitive to fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65dd9188b678a006a3d4c43ff3298b1
https://doi.org/10.1007/s12325-021-01778-8
https://doi.org/10.1007/s12325-021-01778-8
Publikováno v:
Cancers; Volume 14; Issue 8; Pages: 1936
In this analysis, we examined the efficacy, feasibility, and limitations of the application of mTOR inhibitors based on the individual molecular profiles of pretreated cancer patients after the failure of all standard treatments in the palliative set
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7d0263784a27f2dfbacc59c2345f8d
Autor:
Agnieszka Maj-Hes, Péter Nyirády, Zsolt Jurányi, Lukas Püllen, Tamás Fazekas, Boris Hadaschik, Tibor Szarvas, Sabina Sevcenco, Zsuzsa S Kocsis, Gero Kramer, Shahrokh F. Shariat, Viktor Grünwald, Anita Csizmarik, András Béla Hüttl
To assess chromogranin A (CGA) and neuron-specific enolase (NSE) levels and changes in these at different stages of prostatic adenocarcinoma (PCA).Overall, 1095 serum samples from 395 patients, divided into three treatment groups, were analysed; the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0358d0c805698d810056fd4766252abc
https://www.ncbi.nlm.nih.gov/pubmed/32314509
https://www.ncbi.nlm.nih.gov/pubmed/32314509
Determination of circulating prostate specific antigen (PSA) is commonly used in the diagnosis and treatment monitoring of prostate cancer [1]. Presently, PSA testing is performed in centralized laboratories, which is associated with prolonged time b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62248848198fef32aea78ddd856e4ae8
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85061720298
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85061720298
Autor:
Tibor Szarvas, Viktor Grünwald, Stephan Tschirdewahn, Agnieszka Maj-Hes, Boris Hadaschik, Péter Nyirády, Sabina Sevcenco, Anita Csizmarik, Tamás Fazekas, András Béla Hüttl, Melinda Varadi, Shahrokh F. Shariat, Gero Kramer
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 39:296.e11-296.e19
Objectives The rapidly changing treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) calls for biomarkers to guide treatment decisions. We recently identified MMP-7 as a potential serum marker for the prediction of response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf50c180a7ac76b9b1ffe8e4f0335ec9
https://doi.org/10.1016/j.urolonc.2020.09.005
https://doi.org/10.1016/j.urolonc.2020.09.005
Publikováno v:
Advances in therapy. 36(4)
Determination of circulating prostate specific antigen (PSA) is commonly used in the diagnosis and treatment monitoring of prostate cancer [1]. Presently, PSA testing is performed in centralized laboratories, which is associated with prolonged time b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8b04179d2ee7311448cfbb2c6283d8d6
https://pubmed.ncbi.nlm.nih.gov/30778908
https://pubmed.ncbi.nlm.nih.gov/30778908
Autor:
Sabina Sevcenco, Tibor Szarvas, Shahrokh F. Shariat, Boris Hadaschik, Gero Kramer, Stephan Tschirdewahn, Henning Reis, Anita Csizmarik, Agnieszka Maj-Hes, Ulrich Krafft, Péter Nyirády, Christopher Darr, Zsófia Küronya
Publikováno v:
Urologia internationalis. 101(1)
Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca9321e7b3ef156778da130b1e101432
https://pubmed.ncbi.nlm.nih.gov/29949801
https://pubmed.ncbi.nlm.nih.gov/29949801